US 12,234,509 B2
Methods for detection of donor-derived cell-free DNA
Solomon Moshkevich, Menlo Park, CA (US); Bernhard Zimmermann, Manteca, CA (US); Tudor Pompiliu Constantin, Berkley, CA (US); Huseyin Eser Kirkizlar, Los Angeles, CA (US); Allison Ryan, Belmont, CA (US); Styrmir Sigurjonsson, San Jose, CA (US); Felipe Acosta Archila, Foster City, CA (US); and Ryan Swenerton, Millbrae, CA (US)
Assigned to Natera, Inc., San Carlos, CA (US)
Filed by Natera, Inc., San Carlos, CA (US)
Filed on Feb. 2, 2021, as Appl. No. 17/165,592.
Application 17/165,592 is a continuation of application No. 17/252,068, previously published as PCT/US2019/040603, filed on Jul. 3, 2019.
Claims priority of provisional application 62/834,315, filed on Apr. 15, 2019.
Claims priority of provisional application 62/781,882, filed on Dec. 19, 2018.
Claims priority of provisional application 62/715,178, filed on Aug. 6, 2018.
Claims priority of provisional application 62/693,833, filed on Jul. 3, 2018.
Prior Publication US 2021/0198733 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6876 (2018.01)
CPC C12Q 1/6869 (2013.01) [C12Q 1/6851 (2013.01); C12Q 1/6876 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method of preparing a preparation of amplified DNA from a blood sample of a transplant recipient useful for determining likelihood of transplant rejection, comprising:
(a) extracting DNA from the blood sample of the transplant recipient, wherein the DNA comprises donor-derived cell-free DNA and recipient-derived cell-free DNA;
(b) preparing a preparation of amplified DNA by performing targeted amplification at 200-50,000 target loci in a single reaction volume using 200-50,000 target-specific primer pairs to obtain amplification products, wherein the target loci comprise polymorphic loci and non-polymorphic loci, wherein the targeted amplification comprises an annealing step having a length of at least 10 minutes, and wherein each target-specific primer has a concentration of less than 20 nM;
(c) performing high-throughput sequencing on the amplification products to obtain a sequencing readout and quantifying an amount of donor-derived cell-free DNA and in the blood sample based on the sequencing readout;
wherein a cutoff threshold value of donor-derived cell-free DNA for the blood sample of the transplant recipient is scaled according to the amount of total cell-free DNA and on data of at least one of donor height or donor weight; and
wherein the likelihood of transplant rejection is determined based on comparing the amount of donor-derived cell-free DNA or a function thereof to the scaled cutoff threshold value.